The therapeutic potential of HDAC and HAT inhibitors in ischemic stroke has gained increasing attention due to their roles in epigenetic regulation of neuroinflammation, oxidative stress, and neuronal survival. The gene discussed is HDAC9; the disease is ischemic stroke.